News

Long Island experts weigh in after Novo Nordisk ends deal with Hims & Hers over weight loss meds
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
Hims & Hers’ stock plunges. Here’s why Wegovy parent ended its partnership with the company.
Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...
Novo, Hims & Hers engage in war of words after Wegovy deal falls apart
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...
Yahoo Finance5h
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?
Novo Nordisk NVO ended its collaboration agreement with telehealth company Hims & Hers Health HIMS to offer its blockbuster obesity drug Wegovy (semaglutide) at a discounted price to cash-paying ...
StockStory.org on MSN1d
Hims & Hers Health (HIMS) Stock Trades Down, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 29.2% in the morning session after Novo Nordisk, the maker ...
Zacks Investment Research on MSN5d
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...
Novo Nordisk launches weight-loss drug Wegovy in India to compete with Lilly's Mounjaro
Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...